NTU Finds GLP-1 Drugs Slash Cancer Risk
A multinational research team led by National Taiwan University (NTU) Hospital recently achieved a significant breakthrough, publishing their findings in
Read More
Pharma
Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers
Formosa Pharmaceuticals, Inc. (TW: 6838), today announced the submission of a Clinical Trial Application (CTA) to European regulatory authorities to
Read More
Taiwan’s Lotus Pharma inks biosimilars agreement with Alvotech for US and selected Asian markets
Taiwan-based Lotus Pharmaceutical Co. (TW: 1795) has announced a strategic licensing and commercialisation agreement with Alvotech, covering two of Alvotech’s
Read More
Clinical trial partnerships with Australia: A US pharmaceutical firm case study
In the lead up to the Bio Connections Australia 13-14 November, Melbourne conference, we spoke with US-based pharmaceutical firm, Cerebral Therapeutics, who have recently undertaken a proof of concept clinical study in Australia, using a proprietary formulation to treat refractory epilepsy.
Read More
Lumosa Therapeutics partners with Camargo Pharmaceutical Services for the development of its analgesic in the US
Taipei, Taiwan-based Lumosa Therapeutics Co., Ltd., a company focused on developing treatments for neurological and inflammatory disease, announced recently that it had engaged Cincinnati-headquartered Camargo Pharmaceutical Services for regulatory consulting and strategic development services for LT1001 (Naldebain®, dinalbuphine sebacate IM injection) in the US.
Read More
OBI Pharma signs agreement with Abzena for ADC linker technology
Cambridge, UK-headquartered drug development technology and services provider Abzena plc, has signed a licensing agreement and a master services and clinical supply agreement with Taipei, Taiwan biotech OBI Pharma (TPEx: 4174) for its novel site-specific ThioBridge™ antibody drug conjugate (ADC) linker technology to develop OBI’s proprietary ADC, OBI-999 and a series of further ADCs as potential treatments for cancer.
Read More